Fintech

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®

Globenewswire·April 20, 2026 at 12:00 PM

Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groupsDemonstrated...

Original Source

Globenewswire — www.globenewswire.com

Related in Fintech

Amazon, Anthropic Deepen AI Partnership
PYMNTS
Commercial Loans Show US Economy Defies Forecasts
PYMNTS
Zenskar Raises $15 Million for Agentic AI
PYMNTS
Apple Hardware Leader John Ternus to Succeed CEO
PYMNTS

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®

Amazon, Anthropic Deepen AI Partnership

Commercial Loans Show US Economy Defies Forecasts

Zenskar Raises $15 Million for Agentic AI

Apple Hardware Leader John Ternus to Succeed CEO